The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituxima...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Friedberg, Jonathan W., Vose, Julie M., Kelly, Jennifer L., Young, Faith, Bernstein, Steven H., Peterson, Derick, Rich, Lynn, Blumel, Susan, Proia, Nicole K., Liesveld, Jane, Fisher, Richard I., Armitage, James O., Grant, Steven, Leonard, John P.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2011
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3062293/
https://ncbi.nlm.nih.gov/pubmed/21239695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-11-314708
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker